This study investigates the time course of change in calcium in the blood after a pregnant subject takes an oral dose of calcium carbonate (commonly marketed as "Tums"). This information is important for trials investigating whether calcium can reduce postpartum hemorrhage, bleeding after delivery.

Start Date01 Jan 2025

Sponsor / Collaborator

Stanford University

NCT06580782 / Not yet recruitingPhase 4IIT

Calcium Carbonate to Augment Labor Contractions

The investigators think that calcium carbonate can act as an assistive medication to improve contractions during labor.

Start Date01 Nov 2024

Sponsor / Collaborator

Weill Medical College of Cornell University

NCT06293326 / CompletedPhase 1

An Open Label, Single Center, Randomized, Two-way Crossover Parallel Group, Trial to Assess the Mechanism of Action of a Bi-layer Swallowable Tablet (Immediate Release and Sustained Release) Containing Calcium Carbonate Antacid in an Overnight and Day Application as Compared With a Standard, Non-layered (Immediate Release) Calcium Carbonate Swallow Tablet in Fed Healthy Male Participants.

Researchers are looking for a better way to treat people who have heartburn, indigestion, and problems due to excessive stomach acid. These are common problems which can affect daily life and disturb sleep during the night-time. Heartburn is the burning sensation or pain in the chest which occurs when stomach acid rises up in the food pipe (esophagus).
Calcium carbonate tablets are used to treat heartburn, indigestion, and related digestive problems. Calcium carbonate works by neutralizing the excess acid in the stomach. The study treatment is a new bi-layer calcium carbonate tablet that has two layers. One layer quickly releases calcium carbonate aimed to provide quick relief (called immediate release) while the other layer releases calcium carbonate slowly to make the relief last longer (called sustained release).
In this study, bi-layer calcium carbonate tablets will be given to healthy men for the first time. This study will provide information on how the new bi-layer tablet works inside the body.
The main purpose of this study is to learn about how the new bi-layer calcium carbonate tablet changes the average acidity levels (measured using pH) compared to the standard calcium carbonate tablet during the night-time.
For this, researchers will measure the acidity levels in the upper part of the stomach at regular intervals during the night-time.
The participants will be randomly (by chance) assigned to one of two treatment groups:
Participants in the first group will take the treatments at night.
Participants in the second group will take the treatments during the day.
All participants in both groups will take 2 bi-layer tablets and 2 standard tablets after a meal with a gap of 6 to 8 days between treatments. However, in each group, half the participants will receive the bi-layer tablets first while the other half will receive the standard tablets first.
Each participant will be in the study for around 52 days with up to 4 visits to the study site. This includes:
1. visit about 28 days before the treatment starts during which the doctors will confirm that the participant can take part in the study
2. visits for treatment with a gap of 6-8 days between each treatment, and
1 visit 7 to 14 days after the treatment ends during which the doctors will monitor the participants' health.
During the study, the doctors and their study team will:
check participants' overall health by performing tests such as blood and urine tests, and check heart health using an electrocardiogram (ECG)
take images of the stomach at different times after taking the treatment
measure acidity level (pH) using a device called pH probe that is inserted into the upper part of the stomach
ask the participants questions about how easy it is to take the study treatment
ask the participants what adverse events they are having.
An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective of whether they think it is related to the study treatment, or not.
As this study is conducted in healthy men who will not gain any benefit from this treatment, access to the study treatment after the study is not planned.

Start Date06 Mar 2024

Sponsor / Collaborator

Bayer AG

100 Clinical Results associated with Calcium carbonate

100 Translational Medicine associated with Calcium carbonate

100 Patents (Medical) associated with Calcium carbonate

3,062

Literatures (Medical) associated with Calcium carbonate

01 Jan 2025·Biomaterials

Editorial Note: ‘The nanoformula of zoledronic acid and calcium carbonate targets osteoclasts and reverses osteoporosis’ Biomaterials, 296 (2023), 122059

01 Jan 2025·Biomaterials

Local delivery of carboplatin-loaded hydrogel and calcium carbonate enables two-stage drug release for limited-dose radiation to eliminate mouse malignant glioma

Article

Author: Liang, Hsiang-Kuang Tony ; Wei, Ming-Feng ; Hsu, Cheng-Yi ; Chen, Liang-Hsin ; Lin, Jason ; Lin, Feng-Huei

Postoperative radiotherapy remains the gold standard for malignant glioma treatment. Clinical limitations, including tumor growth between surgery and radiotherapy and the emergence of radioresistance, reduce treatment effectiveness and result in local disease progression. This study aimed to develop a local drug delivery system to inhibit tumor growth before radiotherapy and enhance the subsequent anticancer effects of limited-dose radiotherapy. We developed a compound of carboplatin-loaded hydrogel (CPH) incorporated with carboplatin-loaded calcium carbonate (CPCC) to enable two-stage (peritumoral and intracellular) release of carboplatin to initially inhibit tumor growth and to synergize with limited-dose radiation (10 Gy in a single fraction) to eliminate malignant glioma (ALTS1C1 cells) in a C57BL/6 mouse subcutaneous tumor model. The doses of carboplatin in CPH and CPCC treatments were 150 μL (carboplatin concentration of 5 mg/mL) and 15 mg (carboplatin concentration of 4.1 μg/mg), respectively. Mice receiving the combination of CPH-CPCC treatment and limited-dose radiation exhibited significantly reduced tumor growth volume compared to those receiving double-dose radiation alone. Furthermore, combining CPH-CPCC treatment with limited-dose radiation resulted in significantly longer progression-free survival than combining CPH treatment with limited-dose radiation. Local CPH-CPCC delivery synergized effectively with limited-dose radiation to eliminate mouse glioma, offering a promising solution for overcoming clinical limitations.

01 Jan 2025·The American Journal of Surgery

Demystifying delays: Factors associated with timely treatment of adrenocortical carcinoma

Article

Author: Amjad, Wajid ; Passman, Jesse ; Bader, Amanda ; Passman, Jesse E ; Ginzberg, Sara P ; Hwang, Jasmine ; Wachtel, Heather ; Passman, Jesse E. ; Ginzberg, Sara P. ; Gasior, Julia A ; Gasior, Julia A.

BACKGROUNDDelays in management of adrenocortical carcinoma (ACC) may lead to worse outcomes. We assessed for delays in ACC treatment according to sociodemographic factors.METHODSWe performed a retrospective cohort study of patients treated for ACC (2010-2019) utilizing the National Cancer Database. Cox proportional hazards modeling was used to evaluate the associations between sociodemographic, geographic, and clinical factors and time to intervention from diagnosis.RESULTSAcross 1399 subjects treated for ACC, the median time to treatment was 27 days (IQR 15-47). Non-Hispanic Black patients (HR 0.798, p = 0.033) and patients aged 40-64 years (HR 0.800, p = 0.008) were at greater risk of delays in care, whereas female patients (HR 1.169, p = 0.011) and those with metastatic disease (HR 1.176, p = 0.010) received more timely care.CONCLUSIONSOlder age, male sex, and Black race were associated with delays in care for ACC though these delays did not translate to worsened overall survival.

News (Medical) associated with Calcium carbonate

08 Aug 2024

·www.echemi.com

After 2023 Snub, Amneal Clinches Approval for Extended-Release Parkinson's Disease Med Crexont

After a major setback in 2023, Amax Pharmaceuticals finally ushered in a brilliant victory in the United States, its signature innovative delayed release Parkinson's disease treatment drug - Crexont, successfully obtained the authoritative approval of the United States Food and Drug Administration (FDA). This unique oral calcium carbonate/levodopa (CD/LD) extended-release formulation opens a new chapter in the treatment of patients with Parkinson's disease with its superior efficacy and convenience, not only significantly extending their "well" period, but also reducing the number of burdensome daily doses to three times, greatly improving patients' quality of life. The FDA accepted Crexont's application after a thorough review and analysis of the detailed Phase III clinical trial data submitted by Amax. In this critical clinical trial of RISE-PD, Crexont stood out for its exceptional performance, providing patients with an additional 30 precious minutes of "good" time per day compared to traditional ready-to-release CD/LD. In addition, its average daily frequency of taking only three times, compared with five times for traditional drugs, undoubtedly brings unprecedented convenience to patients. The successful approval of Crexont is undoubtedly a significant milestone in the treatment of Parkinson's disease. In the face of the large population of patients in the United States - about 1 million people with Parkinson's disease, and about 90,000 new cases each year, the introduction of Crexont has undoubtedly brought unprecedented hope for patients. The co-ceos of Amax Pharmaceuticals, Chirag Patel and Chintu Patel, could not contain their excitement, saying that it is their greatest honor to bring this epoch-making new treatment to Parkinson's disease patients in the United States. At the same time, the company is also confidently planning to bring this innovative treatment to the international market. However, behind the success is often accompanied by unremitting efforts and challenges. Amax had previously been rejected by the FDA because of insufficient safety data on Crexont. This setback did not break them, but inspired them to be more determined and more rigorous. Now, with the successful approval of Crexont, the drug is expected to generate annual sales of up to $300 million to $500 million, further solidifying its leading position in the treatment of Parkinson's disease. It's worth noting that Amax is not alone. Abbott and Newrod Pharmaceuticals, among others, have faced similar regulatory challenges on the road to developing new levodopa preparations. These experiences show that despite the difficulties ahead, pharmaceutical companies are still working hard to find better treatments for Parkinson's disease. Amax's success has undoubtedly set an example for the entire industry, and has brought more treatment options and light of hope to patients with Parkinson's disease.

Phase 3Drug ApprovalClinical Result

27 Nov 2023

·www.prnewswire.com

Amorphical brings Scientific Breakthrough - Treating and Curing Chronic Inflammatory and Oncological Diseases

NES-ZIONA, Israel, Nov. 27, 2023 /PRNewswire/ -- An exclusive initiative by the Israeli biotechnology company Amorphical brings a breakthrough approach to treating a variety of chronic inflammatory and oncological diseases. Scientific Development and Breakthrough Amorphical has developed a pioneering technology to produce amorphous nano-minerals. The unique structure of these amorphous nano-minerals enables the efficient and rapid absorption of essential minerals in the body. Amorphous nano-minerals also possess a unique ability to stimulate healing mechanisms within the target damaged tissues. Amorphous Calcium Carbonate – Amorphical's Revolutionary Leading Product Calcium is a vital mineral for various physiological activities: bone formation, nerve conductivity, muscle function, boosting the immune system, and many other activities. Carbonate is a crucial molecule for maintaining the body's pH balance by neutralizing excess acidity. Treating the Cause for Disease, Not Just the Symptom Modern lifestyle, characterized by stress, unbalanced diet, and an increase in life expectancy, results in a reduced production of bicarbonate, essential for the proper function of the body. Consequently, the elevated tissue acidity impairs the ability to regulate inflammatory processes, ultimately leading to the development of chronic inflammatory as well as oncological diseases. Due to its unique structure and dissolving properties, unlike the crystalline mineral, the amorphous calcium carbonate can directly target inflamed or cancerous tissues. When amorphous carbonate calcium reaches the inflamed tissue, a neutralizing reaction occurs within the acidic environment. The resulting neutral environment does not support the inflammatory processes, leading to the desired healing. Neutralizing the acidic environment is also crucial in treating oncological diseases. Most oncological diseases are characterized by anaerobic respiration of cancer cells, creating an acidic environment within the tumor. This acidic environment supports the rapid division of cancer cells and the development of metastases, while preventing the immune system from attacking and eliminating the cancer cells. Neutralizing the acidic environment in the cancerous tissue by amorphous calcium carbonate inhibits the enhanced metabolic activity of the cancer cells, required for their rapid division. In parallel to the reduction in cancer cell proliferation, the neutralization of the acidic environment within the tumor allows the immune cells to resume their activity, and attack and destroy the cancer cells. To date, this is the sole technology capable of treating and curing a wide range of oncological diseases by transforming the cancerous environment into a healthy environment. Comparison to Current Medications Current medications for chronic inflammatory diseases primarily aim to alleviate symptoms rather than target the disease accelerator, which is the acidic environment within the inflamed tissue. In contrast, amorphous calcium carbonate neutralizes the acidic environment specifically in the inflamed tissue, and thus enables the healing of the inflammation. Conditions Suitable for Treatment by Amorphous Calcium Carbonate The innovative treatment with amorphous calcium carbonate promotes prompt and effective recovery across a variety of diseases: 1. Crohn's Disease, Multiple Sclerosis, Osteoporosis, Arthritis, Pulmonary diseases, and other chronic inflammatory diseases. 2. A wide range of oncological diseases including breast, prostate, colon, liver cancers, and more. 3. The treatment has proven to be highly effective in managing COVID-19. 4. The treatment significantly slows down aging processes and substantially improves the quality of life. Selected Scientific Publications on the Medical Activity of Amorphical's Nano-Amorphous Calcium Carbonate: Lung Cancer: Amorphous Calcium Carbonate Shows Anti-Cancer Properties That are Attributed to Its Buffering Capacity. Cancers (Basel). 2023 Jul 26;15(15):3785 Treatment for COVID-19: Sublingual and Inhaled Amorphous Calcium Carbonate for Hospitalized Patients with SARS-CoV-2: A Phase 1/2 Clinical Study. J Clin Trials. 2023 Vol.13 Iss. 4 No: 1000551 Effect on Mouse Embryos: The effect of amorphous calcium carbonate as a culture media supplement on embryonic development of murine sibling embryos. J Assist Reprod Genet. 2023 Oct;40(10):2409-2418 Additional articles describing the treatment with Amorphical's amorphous nano-minerals are presented on the company's website. For more information, please contact: Noga Nadel Erental - [email protected] Logo -

20 Nov 2023

·www.biospace.com

BioTech Medics Continues to Execute Its Calcium Business Plans

WOODLAND HILLS, CA / ACCESSWIRE / November 20, 2023 / BioTech Medics, Inc. (OTC PINK:BMCS) is pleased to announce that the Company continues to build the fundamental substructure that will enhance our ability to raise capital to position the organization in a competitive advantage with its calcium carbonate assets to enhance BMCS as a substantial publicly traded firm in this sector. Our website can be found at According to Anthony K. Miller, CEO, "As we previously reported, our business model is in the biotech ecosystem, encompassing calcium, calcium carbonate and related products. This month (November) management met with several brokers and market-makers to update and repost our company's 15c211.This updated 15c211 will allow BMCS stock to be more accessible to a larger market-maker base and remove the warning from our security. This action will add value to current and new shareholders, increase the tradability of our stock and give us greater credibility in the financial community; enhancing our ability to raise working capital. Additionally, management is actively moving to become a reporting issuer and elevate to the OTCQB or greater in 2024. We will also seek to reduce the I/O common shares once revenue starts to enhance our share value… All these activities are necessary so that BMCS can capitalize on its significant opportunities. This week management did BMCS 3Q financial filings and did position the Company's audit-ready financials for an imminent audit. We have solid alliance in the calcium sector, and we are comfortable with marketing our calcium to the larger US marketplace that will include a wide variety of products. Raising money for these opportunities is necessary to liberate all the opportunities before us. We are already entertaining purchase orders, and management will do whatever it can to materialize these opportunities and bring capital forward. Our revenue will begin this year (2023). Management expects that this is a long-term venture (with our own physical assets) lasting more than a decade once fully implemented. OUR FUTURE: This year management (after over 2 years trying to get our name change through FINRA) decided to abandon the name change and the digital asset business plan. Management decided to take the Company 100% back to its biotech roots and did initiate an agreement with certain asset holders in the Dominican Republic with calcium carbonate resources that boast of 3 billion+ metric ton reserves. On September 28, 202 because of a negotiated agreement BioTech Medics procured 2 million metric tons of very high quality (99.8% pure) calcium carbonate to market to a worldwide marketplace. This calcium carbonate has a base value of $30 million dollars (2 million tons @ $15.00 per ton). As management goes into the sales portals it is common that this same calcium carbonate (request for proposals-RFP) has common requested values in excess of $85.00 per metric ton (in the portals). Further note that this was a significant transaction that management negotiated for the firm since the assets were acquired for 2 million Series A preferred shares of stock. Finally, management did procure (along with this transaction) an option to acquire an additional 48 million metric tons of calcium carbonate at a similar transaction value. Our new business plan is an old school commodities plan where we mine our calcium… put in on a truck and then put it on a ship to send it to the client. This business model has traditional profit margins in excess of 33% per transaction. Follow the hyperlink to see actual images taken from our mine (we will continue to post real-time images in the future here)… located on our website commented Miller" About Calcium Carbonate: The global calcium carbonate market size was valued at USD 44.7 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 6.6% from 2023 to 2030. Increasing demand for paper from packaging applications and hygiene-related products like tissue paper is a significant growth driver. The U.S. has been a prominent destination for the product considering high demand from industries. Paper is the largest application segment of the market, and the U.S. is among the world's largest paper manufacturers. Calcium carbonate is also used as organic fertilizer, to produce calcium citrate (citric acid), which is used as a food additive, a preservative, an acidifier, or a flavoring agent. It is used in applications such as cleaning agents, cosmetics, pharmaceuticals, and dietary supplements. As utilized in building material, it helps to manufacture mortar that holds together tiles, rubber products, roofing tiles, concrete slabs and stones and is employed in paints and pigments. Additionally, baking powder, wine, dough, plastics, adhesives sealants and more. It is also used to adjust the pH value of water through the neutralization process. Calcium is a widely utilized commodity with tremendous applications. About BioTech Medics, Inc: BioTech Medics, Inc is a publicly traded Wyoming company traded on the OTC Markets under the stock symbol BMCS located in Los Angeles California. BioTech Medics Inc. has a long and successful history in the biotech sector. The firm going forward will focus on calcium, silica, carbon credits as its business model. Additionally, the firm still has significant other assets and now calcium assets position BMCS above $70 million dollars (transactions before us can increase or reduce those assets… ultimately all our assets are projected be calcium and silica… as the source of our revenue). Forward-Looking Statements: This press release contains "forward-looking statements" within the meaning of the safe harbour provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including those with respect to the expected projects of BioTech Medics, Inc., and related companies. All statements that are included in this Press release, other than statements of historical fact, are forward-looking statements. Forward-looking statements involve known and unknown risks, assumptions, uncertainties, and other factors. Statements made in the future tense, and statements using-words-such as "may, "can," "could," "should," "predict," "aim'" "potential," "continue," "opportunity," "intend " "goal," "estimate," "expect," "expectations," "project," "projections," "plans," "anticipates," "believe," "think," "confident" "scheduled" or similar expressions are intended to identify forward-looking statements. Forward-looking statements are not a guarantee of performance and are subject to a number of risks and uncertainties, many of which are difficult to predict and are beyond our control. These risks and uncertainties could cause actual results to differ materially from those expressed in or implied by the forward-looking statements, and therefore should be carefully considered. You should consider the areas of risk described in connection with any forward-looking statements that may be made herein. We caution you not to place undue reliance on the forward-looking statements, which speak only as of the date of this report and readers should carefully review this report in its entirety. We disclaim any obligation to update any of these forward-looking statements as a result of new information, future events, or otherwise, except as expressly required by law. Further information on our risk factors is contained in our filings with the OTC Markets and the SEC website. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. CONTACT INFORMATION INVESTOR RELATIONS STOCK SYMBOL: (BMCS-OTC) EMAIL: tonymillertmiller@gmail.com or tmiller@biotechmedics.co WEBSITE: PHONE: 800.988.3782/ 661.544.0275 LOCATION: WOODLAND HILLS, CA. SOURCE: BioTech Medics Inc. View source version on accesswire.com:

100 Deals associated with Calcium carbonate

External Link

KEGG	Wiki	ATC	Drug Bank
D00932	Calcium carbonate	A12AA04 A02AC01	DB06724

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hyperphosphatemia	JP	Takeda Pharmaceutical Co., Ltd.	-
Osteoporosis	CN	Haleon (Suzhou) Pharmaceutical Co. Ltd.	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypoparathyroidism	Phase 2	-	-	-
Adrenocortical Carcinoma	Phase 1	IL	Amorphical Ltd.	25 Jun 2017
Bone metastases	Preclinical	IL	Amorphical Ltd.	01 Jun 2022
Castration-Resistant Prostatic Cancer	Preclinical	IL	Amorphical Ltd.	01 Jun 2022
Gastroesophageal Reflux	Discovery	JP	Otsuka Pharmaceutical Co., Ltd.	31 Oct 2017
Secondary malignant neoplasm of lung	Discovery	IL	Amorphical Ltd.	25 Jun 2017
HIV Infections	Discovery	-	ViiV Healthcare Ltd.	01 Dec 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02186600 (HOPS, CTgov)	Phase 3	Osteoporosis	276	Calcium Carbonate+Vitamin D3 (Control)	qdaotjvxea(xqfkkkarxc) = dzrvawimnx kuyjywsfuf (dkrvbhkiyg, flhkuqgiag - jurfsdmdeu) View more	-	27 Jun 2023
				Risedronate+Calcium Carbonate+Vitamin D3 (Risedronate)	qdaotjvxea(xqfkkkarxc) = iyvwrvllkr kuyjywsfuf (dkrvbhkiyg, hfpevxcjja - qqckvucoxy) View more
ERA2022	Not Applicable	Chronic Kidney Diseases skeletal plasma clearance of tracer (K i ) \| bone volume/tissue volume (BV/TV)	-	Sucroferric oxyhydroxide	irpbxoetxo(xmgyzyyuif) = BV/TV (volume) was significantly lower after SO treatment than after CC treatment roddrcspyv (dcytvytrkm )	-	03 May 2022
				Calcium carbonate
NCT01696279 (CTgov)	Phase 2	Hyperphosphatemia \| Chronic Kidney Diseases	63	lanthanum carbonate (Part 2 + Part 3: Lanthanum Carbonate)	uavryjgycc(nqrnjeabtq) = hcrgkulyoz xkunuvujts (bdchkzxost, vytqnmlpoq - qormgoiuwb) View more	-	02 Jan 2020
				calcium carbonate (Part 2: Calcium Carbonate)	bfiukxjgfo(nwikikyriu) = qzwjoyhlet fsthinaazu (yirsvlasmw, zkwgqoylut - ezftkiqxxi) View more
ASN2019	Not Applicable	-	53	Denosumab 60mg s.c.	(hojvbohwvf) = Hypocalcemia is frequent in HD patients after use of denosumab. Intravenous calcium replacement is needed in patients with severe hypocalcemia fwbsxqvvwr (vymzvkadwo ) View more	Positive	05 Nov 2019
				Dicamax(cholecalciferol 1000 IU and calcium carbonate 1250mg)
ASN2019	Not Applicable	-	37	Calcium Carbonate	bmnjidacdy(dodaynsudm) = dmvzzopncn ryirwsabrz (jsdcbreria, 7 - 14) View more	Negative	05 Nov 2019
				Sevelamer	bmnjidacdy(dodaynsudm) = darwhjlcvk ryirwsabrz (jsdcbreria, 3 - 19) View more
NCT03089216 (CTgov)	Phase 4	Dentin Sensitivity	108	Combined Bleaching(2x20) (Combined Bleaching(2x20))	etudqagcln(ktmlnoodvr) = ecemecgpbi osrwsfwovw (kircjijdhd, hdvrdxeikk - wvpgsxfdhi) View more	-	05 Aug 2019
				Combined Bleaching (1x20) (Combined Bleaching(1x20))	etudqagcln(ktmlnoodvr) = ilrznpiirf osrwsfwovw (kircjijdhd, bxqgjpbajp - vpbroageba) View more
NCT00436475 (CaDDM, CTgov)	Phase 1/2	Diabetes Mellitus, Type 2 \| Metabolic Syndrome \| Glucose Intolerance	92	Vitamin D (Vitamin D-Calcium)	yfgmwhrfid(fmkamsjzet) = ulxkxubsoj xjjceijbvf (rxxrlgsrsz, zdzqpsjqtn - bynpraispr) View more	-	30 Jul 2019
				Vitamin D (Vitamin D Only)	yfgmwhrfid(fmkamsjzet) = rtbxftdoaq xjjceijbvf (rxxrlgsrsz, qnhbkllfhz - vimobcqxni) View more
ISN WCN2019	Not Applicable	-	-	Calcium Carbonate	dvwceyymrb(zvzxntceta) = ytglrwonvk cxjqmfaduh (tozbmcotur )	-	01 Jul 2019
				Sevelamer Hydrochloride	dvwceyymrb(zvzxntceta) = awbcssjxve cxjqmfaduh (tozbmcotur )
ASN2018	Not Applicable	osteocalcin \| bone alkaline phosphatase \| tartrate-resistant acid phosphatase 5b ... View more	65	Lanthanum Carbonate	spybxyozjh(ipefwewpiv) = lgryyrrurc xdmyuxlvdp (gilqnbjste, 18.9 - 53.2) View more	Positive	23 Oct 2018
				Calcium Carbonate	spybxyozjh(ipefwewpiv) = ynvmtvhnuq xdmyuxlvdp (gilqnbjste, 15.3 - 28.3) View more
ASN2016	Not Applicable	Maintenance	98	Oral calcium carbonate	ilnvkmhlcw(cidcddxzxt) = aahchmonrp xbipszvtdk (zigoxgcliw ) View more	Negative	15 Nov 2016

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis